Emyria (ASX:EMD) reported a reduction in the symptoms of patients diagnosed with post-traumatic stress disorder (PTSD) who underwent its therapy program, according to a Tuesday filing with the Australian bourse.
The program showed an average reduction of 29.6 points in PCL-5 scores, which are used in assessing PTSD severity, per the filing.
Additionally, a scale measuring patients' quality of life improved by an average of 23.5 points under the program.
The results are based on an interim analysis of the first eight patients who completed Emyria's MDMA-assisted therapy for PTSD.
Emyria's shares were up nearly 3% in recent Tuesday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。